The annual meeting of the European Association for the Study of the Liver (EASL) took place in Paris from 11 to 15 April. The event was attended by some 10,000 people from all over the world and was also attended by several Humanitas specialists.
In particular, Dr. Lorenza Rimassa, Vice Director of the Medical Oncology Operational Unit in Humanitas, conducted a report on the role of the medical oncologist in the multidisciplinary management of hepatocarcinoma at the joint EASL-ESMO (European Society for Medical Oncology) symposium.
Hepatocarcinoma: the need for joint work
“A joint symposium with the European Society of Medical Oncology (ESMO) was organized during EASL; it is one of the first meetings where this is taking place and it is an important signal that underlines the need for synergistic work between hepatologists and medical oncologists in the treatment of patients with liver cancer,” Dr. Rimassa explained.
The symposium was attended by Professor Bruno Sangro, Director of the Liver Unit at Clínica Universidad de Navarra and Professor of Medicine at the University of Navarra School of Medicine, and Dr. Lorenza Rimassa. She highlighted the role of the medical oncologist in the treatment of hepatocarcinoma and presented the latest available data on the disease.
The management of hepatocarcinoma requires a continuum of skills that includes medical oncology, hepatology and surgery, a joint work that allows you to optimize the treatment of this disease thanks to the multidisciplinary approach and thus allows the adoption of increasingly personalized treatment strategies.
Next appointment in September in London
Oncologists, hepatologists and surgeons will meet once again at ILCA 2018, an interdisciplinary meeting organized by the International Liver Cancer Association and dedicated to liver cancer, which will take place in London from 14 to 16 September. This appointment again underlines the need for multidisciplinary work for the complete benefit of patients.